Bio-Rad Laboratoriesvs.Labcorp
BIO vs LH · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Labcorp is about 2.6× larger than Bio-Rad Laboratories by market cap; Labcorp trades at the lower P/E (25.3 vs 44.1); year to date, Labcorp leads (+25.2% vs +18.9%).
Supply-chain link: Bio-Rad Laboratories supplies Labcorp.
Side by side
| BIO | LH | |
|---|---|---|
| Market cap | $9.8B | $25.3B |
| Price | $366.16 | $312.15 |
| Today | +1.6% | −0.7% |
| Return YTD | +18.9% | +25.2% |
| Return 1Y | +19.0% | +13.2% |
| Since June 26, 2026 | +21.7% | +15.0% |
| P/E | 44.1 | 25.3 |
| P/S | 3.8 | 1.8 |
| P/B | 1.4 | 2.9 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Bio-Rad LaboratoriesBIO
Clinical diagnostics laboratories buy one part of the range, blood typing among the uses; life science researchers buy the other, for work such as droplet digital PCR.
Full BIO profile →LabcorpLH
Samples from across the US end up in Labcorp's laboratories, which handle routine clinical testing alongside genomics and specialty assays. A contract research arm works for drug developers.
Full LH profile →More BIO & LH comparisons
Other head-to-heads in the Diagnostics segment.